Inside Takeda’s Plasma-Derived Therapy Ecosystem [Forbes]
Grifols, S.A. - American Depositary Shares (GRFS)
Last grifols, s.a. - american depositary shares earnings: 5/7 07:27 am
Check Earnings Report
US:NASDAQ Investor Relations:
grifols.com/en/web/international/investor-relations/home-page
Company Research
Source: Forbes
Takeda Pharmaceuticals Takeda's (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda's Plasma-Derived Therapies Business Unit and chair of the Plasma Protein Therapeutics Association global executive board of directors, tackles complex logistical and economic challenges, collecting about 15 million liters of blood plasma annually from millions of donations and transforming it into medicines. The PDT industry includes other major players such as CSL Behring, a division of CSL Limited (ASX:CSL), and Grifols (NASDAQ: GRFS) also working to meet the increasing demand for these life-saving treatments. In 2024, the global PDT market was valued between $21.54 billion and $28.12 billion, depending on the source, and is projected to reach between $43.91 billion and $46.7 billion by 2031, growing at a compound annual growth rate (CAGR) of approximately 6.3% to 7.1%. The industry relies heavily on plasma sourced from a handful of countrie
Show less
Read more
Impact Snapshot
Event Time:
GRFS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRFS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRFS alerts
High impacting Grifols, S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GRFS
News
- Grifols (NASDAQ:GRFS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Grifols (NASDAQ:GRFS) had its price target lowered by analysts at JPMorgan Chase & Co. from $10.30 to $10.00. They now have a "neutral" rating on the stock.MarketBeat
- Grifols (NASDAQ:GRFS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Grifols SA (GRFS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... [Yahoo! Finance]Yahoo! Finance
- Grifols (NASDAQ:GRFS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
GRFS
Analyst Actions
- 12/8/25 - JP Morgan
GRFS
Sec Filings
- 12/16/25 - Form 6-K
- 11/12/25 - Form SCHEDULE
- 11/4/25 - Form 6-K
- GRFS's page on the SEC website